^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Hairy Cell Leukemia
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Study of the clinical activity and safety of dabrafenib (Tafinlar) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutation

    Excerpt:
    ...Proven diagnosis of HCL according to the morphological and immunophenotypic criteria (co-expression of CD11c/CD25/CD103 and/or positivity for annexin-A1) of the World Health Organization (WHO-2008) classification of lymphoid neoplasms, accompanied by the presence of the BRAF-V600E mutation as detected using a sensitive allele-specific polymerase chain reaction (AS-PCR). ...
    Trial ID:
    2014-001379-29
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia

    Published date:
    11/04/2020
    Excerpt:
    ...we have shown that dabrafenib as a single agent or combined with rituximab is a safe and effective therapy in BRAF V600E mutated HCLc, even in those patients with prior time limited duration BRAFi therapy.
    DOI:
    https://doi.org/10.1182/blood-2020-137531